These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19198962)

  • 21. The effect of long-term alendronate treatment on cortical thickness of the proximal femur.
    Unnanuntana A; Ashfaq K; Ton QV; Kleimeyer JP; Lane JM
    Clin Orthop Relat Res; 2012 Jan; 470(1):291-8. PubMed ID: 21773861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.
    Ing-Lorenzini K; Desmeules J; Plachta O; Suva D; Dayer P; Peter R
    Drug Saf; 2009; 32(9):775-85. PubMed ID: 19670917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features.
    Chan SS; Rosenberg ZS; Chan K; Capeci C
    AJR Am J Roentgenol; 2010 Jun; 194(6):1581-6. PubMed ID: 20489100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.
    Patel VC; Lazzarini AM
    Orthopedics; 2010 Oct; 33(10):775. PubMed ID: 20954650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VISUAL VIGNETTE.
    Ayyoub S; Coyne C
    Endocr Pract; 2018 Nov; 24(11):1020. PubMed ID: 30106629
    [No Abstract]   [Full Text] [Related]  

  • 26. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate.
    Cheung RK; Leung KK; Lee KC; Chow TC
    Hong Kong Med J; 2007 Dec; 13(6):485-9. PubMed ID: 18057440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report.
    Sayed-Noor AS; Sjödén GO
    Acta Orthop; 2008 Aug; 79(4):565-7. PubMed ID: 18766492
    [No Abstract]   [Full Text] [Related]  

  • 28. Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
    Gopal GK; Tam KL; Krishnan SP; Maddern IL
    N Z Med J; 2014 Feb; 127(1389):81-5. PubMed ID: 24548959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical femoral fractures bilaterally in a patient receiving denosumab.
    Drampalos E; Skarpas G; Barbounakis N; Michos I
    Acta Orthop; 2014 Feb; 85(1):3-5. PubMed ID: 24171686
    [No Abstract]   [Full Text] [Related]  

  • 30. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.
    Lenart BA; Neviaser AS; Lyman S; Chang CC; Edobor-Osula F; Steele B; van der Meulen MC; Lorich DG; Lane JM
    Osteoporos Int; 2009 Aug; 20(8):1353-62. PubMed ID: 19066707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can long-term bisphosphonate use causes low-energy fractures? A case report.
    Dandinoğlu T; Akarsu S; Karadeniz M; Tekin L; Arıbal S; Kıralp MZ
    Osteoporos Int; 2014 Feb; 25(2):773-6. PubMed ID: 23824297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonate-related subtrochanteric femoral fractures.
    Gunawardena I; Baxter M; Rasekh Y
    Am J Geriatr Pharmacother; 2011 Jun; 9(3):194-8. PubMed ID: 21470918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Femoral fractures in osteoporotic patients on bisphosphonates. A case report.
    Alshahrani F; Kendler D
    J Clin Densitom; 2012; 15(3):380-4. PubMed ID: 22572530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture.
    Fernandes TL; Viezzer Fernandes B; Jitumori C; Franco GCN
    Am J Case Rep; 2023 Oct; 24():e941144. PubMed ID: 37867315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.
    Abrahamsen B; Eiken P; Eastell R
    J Clin Endocrinol Metab; 2010 Dec; 95(12):5258-65. PubMed ID: 20843943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Femoral canal obliteration secondary to prolonged alendronate use: a case report.
    Lim CT; Setiobudi T; Das De S
    J Orthop Surg (Hong Kong); 2012 Apr; 20(1):115-7. PubMed ID: 22535826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy.
    Porrino JA; Kohl CA; Taljanovic M; Rogers LF
    AJR Am J Roentgenol; 2010 Apr; 194(4):1061-4. PubMed ID: 20308511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
    Angthong C; Angthong W
    J Med Assoc Thai; 2011 Dec; 94 Suppl 7():S214-20. PubMed ID: 22619933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy.
    Ahn JK; Lee J; Cha HS; Koh EM
    Rheumatol Int; 2011 Jul; 31(7):973-5. PubMed ID: 20383511
    [No Abstract]   [Full Text] [Related]  

  • 40. Sequential subtrochanteric femoral fracture after atypical diaphyseal fracture in a long-term bisphosphonate user: a case report.
    Park KT; Lee KB
    Acta Chir Orthop Traumatol Cech; 2015; 82(2):157-60. PubMed ID: 26317188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.